Brooke McCormick

1 week ago | ajmc.com | Brooke McCormick

Concurrent hypertension and type 2 diabetes significantly increase mortality risk, according to a study published in Diabetes Care, highlighting the need for targeted interventions to extend the healthspan of individuals in the US.1 The researchers explained that hypertension and type 2 diabetes are consistently among the leading contributors to morbidity and cardiovascular mortality, both in the US and globally.2 Although previous studies have shown that each condition independently...

1 week ago | ajmc.com | Brooke McCormick |Lindsey Leininger |Allister Chang

On this episode of Managed Care Cast, The American Journal of Managed Care® speaks with Lindsey Leininger, PhD, health policy professor and faculty director of the Center for Health Care at the Tuck School of Business at Dartmouth College, and Allister Chang, MPA, co-founder of Fabric Health, a social-impact startup that aims to improve community well-being by transforming everyday moments in laundromats into opportunities to build trust, support Medicaid recertification, and connect families...

1 week ago | ajmc.com | Brooke McCormick

Although non-Hispanic Asian or Pacific Islander populations had the lowest overall ovarian cancer mortality rate, disaggregated data revealed subgroup disparities, according to 2 abstracts published ahead of the 2025 American Society of Clinical Oncology Annual Meeting, underscoring the importance of recognizing the diversity within this racial group.1,2 Despite being the second most common gynecological cancer in the US, ovarian cancer causes the highest mortality among all female...

2 weeks ago | ajmc.com | Brooke McCormick |Gerard J. Criner

Earlier today, the FDA approved mepolizumab (Nucala; GSK) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. The approval was supported in part by findings from the phase 3 MATINEE trial (NCT04133909).

2 weeks ago | ajmc.com | Brooke McCormick

Evernorth, Cigna's health services division, secured a $200 monthly co-pay cap for the antiobesity medications semaglutide (Wegovy; Novo Nordisk) and tirzepatide (Zepbound; Eli Lilly) through direct negotiations with manufacturers.1 The move comes as federal efforts to reduce prescription drug costs continue to gain momentum.2 Evernorth described the initiative as a first-of-its-kind pharmacy benefit that offers savings, choice, and predictability to both patients and health plan sponsors.1...